In the past week, PRPH stock has gone down by -5.63%, with a monthly gain of 39.96% and a quarterly plunge of -41.80%. The volatility ratio for the week is 17.52%, and the volatility levels for the last 30 days are 25.68% for ProPhase Labs Inc. The simple moving average for the past 20 days is -11.76% for PRPH’s stock, with a -80.36% simple moving average for the past 200 days.
Is It Worth Investing in ProPhase Labs Inc (NASDAQ: PRPH) Right Now?
Company’s 36-month beta value is -0.58.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PRPH is 26.37M, and currently, short sellers hold a 6.30% ratio of that floaft. The average trading volume of PRPH on March 17, 2025 was 9.75M shares.
PRPH) stock’s latest price update
The stock of ProPhase Labs Inc (NASDAQ: PRPH) has decreased by -7.78 when compared to last closing price of 0.43.Despite this, the company has seen a loss of -5.63% in its stock price over the last five trading days. globenewswire.com reported 2025-03-07 that GARDEN CITY, NY, March 07, 2025 (GLOBE NEWSWIRE) — ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics, and consumer products company, today announced that Ted Karkus, CEO, will be presenting at this year’s Investor Summit Virtual on March 11th.
Analysts’ Opinion of PRPH
Many brokerage firms have already submitted their reports for PRPH stocks, with H.C. Wainwright repeating the rating for PRPH by listing it as a “Buy.” The predicted price for PRPH in the upcoming period, according to H.C. Wainwright is $12 based on the research report published on December 20, 2021 of the previous year 2021.
Dawson James gave a rating of “Buy” to PRPH, setting the target price at $25 in the report published on January 20th of the previous year.
PRPH Trading at -17.23% from the 50-Day Moving Average
After a stumble in the market that brought PRPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -94.75% of loss for the given period.
Volatility was left at 25.68%, however, over the last 30 days, the volatility rate increased by 17.52%, as shares surge +15.47% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.43% lower at present.
During the last 5 trading sessions, PRPH fell by -5.63%, which changed the moving average for the period of 200-days by -92.23% in comparison to the 20-day moving average, which settled at $0.4449. In addition, ProPhase Labs Inc saw -48.14% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for PRPH
Current profitability levels for the company are sitting at:
- -2.78 for the present operating margin
- -0.32 for the gross margin
The net margin for ProPhase Labs Inc stands at -2.18. The total capital return value is set at -0.56. Equity return is now at value -58.71, with -30.25 for asset returns.
Based on ProPhase Labs Inc (PRPH), the company’s capital structure generated 0.44 points at debt to capital in total, while cash flow to debt ratio is standing at -0.48. The debt to equity ratio resting at 0.78. The interest coverage ratio of the stock is -12.6.
Currently, EBITDA for the company is -14.83 million with net debt to EBITDA at -1.07. When we switch over and look at the enterprise to sales, we see a ratio of 3.2. The receivables turnover for the company is 0.4for trailing twelve months and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.47.
Conclusion
In a nutshell, ProPhase Labs Inc (PRPH) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
